000 04171nam a22005535i 4500
001 978-1-60327-333-6
003 DE-He213
005 20140220084512.0
007 cr nn 008mamaa
008 100301s2010 xxu| s |||| 0|eng d
020 _a9781603273336
_9978-1-60327-333-6
024 7 _a10.1007/978-1-60327-333-6
_2doi
050 4 _aRC321-580
072 7 _aPSAN
_2bicssc
072 7 _aMED057000
_2bisacsh
082 0 4 _a612.8
_223
100 1 _aNeve, Kim A.
_eeditor.
245 1 4 _aThe Dopamine Receptors
_h[electronic resource] /
_cedited by Kim A. Neve.
264 1 _aTotowa, NJ :
_bHumana Press :
_bImprint: Humana Press,
_c2010.
300 _aXII, 648p. 69 illus., 6 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aThe Receptors
505 0 _aHistorical Overview: Introduction to the Dopamine Receptors -- Gene and Promoter Structures of the Dopamine Receptors -- Structural Basis of Dopamine Receptor Activation -- Dopamine Receptor Subtype-Selective Drugs: D1-Like Receptors -- Dopamine Receptor Subtype-Selective Drugs: D2-Like Receptors -- Dopamine Receptor Signaling: Intracellular Pathways to Behavior -- Dopaminergic Modulation of Glutamatergic Signaling in Striatal Medium Spiny Neurons -- Regulation of Dopamine Receptor Trafficking and Responsiveness -- Dopamine Receptor-Interacting Proteins -- Dopamine Receptor Oligomerization -- Dopamine Receptor Modulation of Glutamatergic Neurotransmission -- Unraveling the Role of Dopamine Receptors In Vivo: Lessons from Knockout Mice -- Dopamine Receptors and Behavior: From Psychopharmacology to Mutant Models -- Dopamine Modulation of the Prefrontal Cortex and Cognitive Function -- In Vivo Imaging of Dopamine Receptors -- Dopamine Receptors and the Treatment of Schizophrenia -- Dopamine Receptor Subtypes in Reward and Relapse -- Dopamine Receptors and the Treatment of Parkinson’s Disease -- Dopamine Receptor Genetics in Neuropsychiatric Disorders.
520 _aDopamine receptors are among the most validated drug targets for neuropsychiatric disorders such as schizophrenia and Parkinson’s disease, and are potential targets for other disorders such as substance abuse, depression, Tourette’s syndrome, and attention deficit hyperactivity disorder. The new knowledge brought from the creation and characterization of mice deficient in each of the subtypes and the development of increasingly subtype-selective agonists and antagonists has fueled many of the chapters new to this second edition, with the use of knock-out mice and subtype-selective drugs meriting discussion in stand-alone chapters. The field of G protein-coupled receptors has also advanced significantly since the first edition, with a model of GPCR signaling based on linear, compartmentalized pathways having been replaced by a more complex, richer model in which neurotransmitter effects are mediated by a signalplex composed of numerous signaling proteins, including multiple GPCRs, other types of receptors, such as ionotropic receptors, accessory and scaffolding proteins, and effectors. This second edition of Dopamine Receptors will be of interest to neurobiologists, pharmacologists and molecular biologists who study the brain, as well as neurologists working on psychiatric diseases.
650 0 _aMedicine.
650 0 _aHuman physiology.
650 0 _aNeurosciences.
650 0 _aToxicology.
650 0 _aPharmaceutical technology.
650 0 _aNeurology.
650 0 _aNeurobiology.
650 1 4 _aBiomedicine.
650 2 4 _aNeurosciences.
650 2 4 _aPharmacology/Toxicology.
650 2 4 _aNeurobiology.
650 2 4 _aNeurology.
650 2 4 _aHuman Physiology.
650 2 4 _aPharmaceutical Sciences/Technology.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9781603273329
830 0 _aThe Receptors
856 4 0 _uhttp://dx.doi.org/10.1007/978-1-60327-333-6
912 _aZDB-2-SBL
999 _c110787
_d110787